Howard Frazier.

Delgado, III, M.D., James W. Long, M.D., Ph.D., Thomas C. Wozniak, M.D., Waqas Ghumman, M.D., David J. Farrar, Ph.D., and O. Howard Frazier, M.D. For the HeartMate II Investigators: Advanced Heart Failing Treated with Continuous-Circulation Left Ventricular Assist Device.. Tag S. Slaughter, M.D., Joseph G. Rogers, M.D., Carmelo A. Milano, M.D., Stuart D. Russell, M.D., John V. Conte, M.D., David Feldman, M.D., Ph.D., Benjamin Sun, M.D., Antone J.For the CAP-START Study Group: Antibiotic Treatment Approaches for Community-Acquired Pneumonia in Adults Community-acquired pneumonia is usually a leading cause of hospitalization and death world-wide.1-3 Most guidelines recommend that antibiotic treatment be in line with the severity of disease at demonstration, assessed either based on the level of treatment needed or based on a prognostic risk score. These suggestions have increased the use of macrolides and fluoroquinolones, although these antibiotic classes have been associated with increased advancement of resistance.7,8 The data in support of these recommendations is bound.9-13 The recommendation to include a macrolide to a beta-lactam is founded on observational studies, which are prone to confounding by indication.14 Although fluoroquinolones have already been evaluated in randomized, controlled trials, their superiority over beta-lactam monotherapy is not demonstrated.15,16 Moreover, the full total results of randomized, controlled trials may be affected by in-hospital antibiotic exposure occurring before randomization17, 18 and also have restrictive inclusion criteria often, which limit the generalizability of their results to daily practice.